Bringing the Oncology Community Together
Radium-223 Production Halted Due to Manufacturing Glitch
Production of the prostate cancer drug radium-223 has been temporarily suspended by its maker, Bayer HealthCare Pharmaceuticals, due to a manufacturing problem.
Read More >>
Advancing Prostate Cancer Care
Hopkins Researcher Discusses AR-V7 and Resistance to AR-Targeting Agents
Vogelzang Disputes ‘Weak’ Guideline Rating for Sipuleucel-T
New Data Provide Insight Into Optimal Pre-Chemo Treatments for mCRPC
Infections After Prostate Biopsy Are On the Rise, Large Study Shows
Link May Exist Between Baldness and Aggressive Prostate Cancer
View More >>
- A Network of Your Peers
View more >>
Radium-223: Treatment Considerations
Dr. Antonarakis on AR-V7 and Resistance to AR-Targeting Agents in mCRPC
Antiandrogens—Differences and Sequencing
Most Popular Right Now
Tweets by @OncLive
Genomic Testing for Newly Diagnosed Low-Risk Prostate Cancer
E. David Crawford, MD, Steven E. Canfield, MD, Marc A. Dall'Era, MD, and Neal Shore, MD, discuss genomic testing for newly diagnosed, low-risk prostate cancer.
Updates in the Management of CRPC
Moderated by Raoul S. Concepcion, MD, this panel discussion includes expert perspectives from Neal D. Shore, MD, Paul R. Sieber, MD, E. David Crawford, MD, and Mark S. Austenfeld, MD.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.